Immutep IMMP 深 沪
等待开盘 09-28 09:30:00 美东时间
0.2635
+0.002
+0.57%
华盛通- 最 高0.278
- 今 开0.278
- 成交量 65.85万股
- 最 低 0.2561
- 昨 收 0.262
- 总市值 3883.26万
- 52周最高 3.5299
- 市盈率 静 --
- 换手率 0.45%
- 52周最低 0.2561
- 委 比 83.49%
- 总股本 1.47亿
- 历史最高 7.95
- 量 比 1.59
- 振 幅 8.36%
- 历史最低 0.2561
- 每 手 1
- 风险率 1.05%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immutep announces 1-for-20 ADS ratio change
Immutep (IMMP) will change its ADS ratio from 1 ADS = 10 ordinary shares to 1 ADS = 200 ordinary shares, effective September 28, 2026. The change is equivalent to a 1-for-20 reverse split of ADSs, wit...
09-21 21:06
Change to American Depositary Share Ratio
Immutep Limited announced a change to its ADS ratio, effective September 28, 2026, to address Nasdaq's minimum bid price requirement. The ratio will change from 1 ADS representing 10 ordinary shares to 1 ADS representing 200 ordinary shares, equivalent to a 1:20 reverse split. This adjustment aims to help the company regain compliance with Nasdaq listing rules, as its ADS bid price fell below $1.00 for 30 consecutive days. The change does not aff...
09-21 12:00
Immutep Adjusts ADS Ratio to Safeguard Nasdaq Listing
Immutep Ltd ( ($AU:IMM) ) has provided an announcement. Immutep has announced a...
09-21 10:52
Immutep shares are trading higher after the company issued an update on its development strategy for eftilagimod alfa.
Immutep shares are trading higher after the company issued an update on its development strategy for eftilagimod alfa.
09-12 01:49
Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)
Immutep Limited announced updates on its eftilagimod alfa (efti) development strategy, focusing on head and neck squamous cell carcinoma (HNSCC) in PD-L1 negative patients (CPS < 1) and the neoadjuvant setting of soft tissue sarcoma (STS). A root cause analysis following the discontinuation of the TACTI-004 study identified manufacturing differences between efti produced at 200 L and 2,000 L scales, leading to a new 200 L manufacturing run. The c...
09-11 12:00
Immutep Refocuses Efti Development After Manufacturing Probe
An announcement from Immutep Ltd ( ($AU:IMM) ) is now available. Immutep has ou...
09-11 07:17
Immutep Posts Higher FY2026 Loss Despite New Licensing Revenue
Immutep ( ($IMMP) ) has issued an update. Immutep Limited has released its audi...
09-02 18:28
Immutep Quarterly Activities Report Q4 FY26
Immutep Limited provided an update on its activities for Q4 FY26, highlighting progress in its eftilagimod alfa (efti) program and IMP761 development. Pooled analysis of five efti trials showed a 7.7-month median overall survival benefit in biological responders across four tumor types. IMP761, the only LAG-3 agonist antibody in clinical development, met its primary safety endpoint and demonstrated significant pharmacodynamic activity in a first-...
07-30 12:00
Immutep balances TACTI-004 setback with upbeat efti and IMP761 data
Immutep Ltd ( ($AU:IMM) ) has issued an announcement. Immutep’s latest quarterl...
07-30 06:55
Immutep’s Sarcoma Quality-of-Life Data Accepted for ESMO 2026
Immutep Ltd ( ($AU:IMM) ) has shared an update. Immutep has had an abstract acc...
07-24 07:18
